top of page

Our Strategy

Utilizing biological mediators and pathways, FibroGen is accelerating a pipeline of treatments focusing on cancer and its related conditions.

Our near-term strategies include:


  • Completion of two late-stage pivotal studies of pamrevlumab in pancreatic cancer.

  • Progression of supplemental new drug application filed with the China Health Authority by FibroGen and our partner AstraZeneca for roxadustat in patients with chemotherapy-induced anemia with an expected approval decision in mid-2024.

  • Initiation of a Phase II trial of FG-3246 for metastatic castration-resistant prostate cancer in the second half of 2024.

  • Accelerating our early-stage oncology pipeline.

  • Continued market growth of roxadustat in China.


FibroGen China

Learn about our Beijng subsidiary and our
operations in China

bottom of page